Skip to main content

Omnicell Value Stock - Dividend - Research Selection

Omnicell

ISIN: US68213N1090 , WKN: 632313

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Omnicell, Inc. provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications. The company also provides XR2 Central Pharmacy System, a hospital pharmacy robotics system; Central and Satellite Pharmacy Manager, an automated pharmacy storage and retrieval system; Controlled Substance Management, a controlled substance inventory management system; OmniLinkRx, a prescription routing system; and WorkflowRx, an automated pharmacy storage, retrieval, and packaging system. In addition, it offers Omnicell Supply Management System, an automated dispensing system; Omnicell Tissue Center, which manages the chain of custody for bone and tissue specimens; OptiFlex MS that manages medical and surgical supplies; OptiFlex SS, a module for the perioperative areas; and OptiFlex CL, a module for the cardiac catheterization lab and other procedure areas. Further, the company provides IV Solutions; enterprise analytics and solutions; Omnicell Interface Software; Mach4 Pharma Systems Medimat, a robotic dispensing system; Omnicell SupplyX subscription software; RFID solutions; and consumable medication blister cards, packaging equipment, and ancillary products and services to institutional pharmacies. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was founded in 1992 and is headquartered in Mountain View, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Omnicell (OMCL) Is Down 19.0% After Profit Squeeze Despite Solid 2026 Revenue Outlook - What's Changed

2026-02-12
In early February 2026, Omnicell reported fourth-quarter 2025 revenue of US$313.98 million with a small net loss of US$2.03 million, and issued first-quarter 2026 revenue guidance of US$300 million to US$310 million plus full-year 2026 guidance of US$1.22 billion to US$1.26 billion. The results highlighted pressure on profitability despite revenue growth, even as management pointed to strong demand for XT S10 devices and a multi-year Titan XT refresh opportunity exceeding US$2.50 billion. We...

The Top 5 Analyst Questions From Omnicell’s Q4 Earnings Call

2026-02-12
Omnicell’s fourth quarter was met with a significant negative market reaction, as the company delivered revenue in line with Wall Street expectations but posted a notable shortfall in non-GAAP profitability. Management attributed the quarter’s performance to robust demand for its point-of-care connected devices, particularly the XT S10, and highlighted strong annual recurring revenue momentum. However, mix shifts in product and customer base, as well as higher operating costs tied to new product

Omnicell, Inc. 2025 Q4 - Results - Earnings Call Presentation

2026-02-08
2026-02-08. The following slide deck was published by Omnicell, Inc.

Piper Sandler Reiterates Overweight on Omnicell, Lowers Price Target to $49

2026-02-06
Piper Sandler analyst Jessica Tassan reiterates Omnicell (NASDAQ:OMCL) with a Overweight and lowers the price target from $63 to $49.

OMCL Q4 Deep Dive: Product Launches, Tariff Headwinds, and Margin Pressures Shape Outlook

2026-02-06
Healthcare tech company Omnicell (NASDAQ:OMCL) met Wall Street’s revenue expectations in Q4 CY2025, with sales up 2.3% year on year to $314 million. The company expects next quarter’s revenue to be around $305 million, coming in 8.2% above analysts’ estimates. Its non-GAAP profit of $0.40 per share was 19.4% below analysts’ consensus estimates.

Omnicell Q4 Earnings Call Highlights

2026-02-06
Omnicell (NASDAQ:OMCL) reported what management described as a “solid finish” to fiscal year 2025, with fourth-quarter total revenue, bookings, and annual recurring revenue (ARR) all coming in above the midpoint of the company’s prior guidance ranges. Executives highlighted strength in the company’s

Omnicell Inc (OMCL) Q4 2025 Earnings Call Highlights: Strong Demand and Strategic Innovations ...

2026-02-05
Omnicell Inc (OMCL) surpasses revenue expectations with new product launches, despite facing tariff challenges and a dip in gross margins.

Omnicell, Inc. (OMCL) Q4 2025 Earnings Call Transcript

2026-02-05
Omnicell, Inc. (OMCL) Q4 2025 Earnings Call February 5, 2026 8:30 AM ESTCompany ParticipantsKathleen Nemeth - Senior Vice President of Investor...

Assessing Omnicell (OMCL) Valuation After Recent Share Price Gains And High P/E Multiple

2026-02-05
Omnicell (OMCL) is back on many watchlists after recent trading, with the stock last closing at $46.69. Investors are weighing this price against the company’s fundamentals and recent return profile. See our latest analysis for Omnicell. The recent 1 day share price return of 1.41% comes after a mixed stretch, with a 7 day share price return of 4.79% and a 30 day share price return of 0.51%. The 90 day share price return of 30.56% contrasts with a 5 year total shareholder return of 64.65%. If...

Why Omnicell (OMCL) Shares Are Plunging Today

2026-02-05
Shares of healthcare tech company Omnicell (NASDAQ:OMCL) fell 18.4% in the morning session after the company reported fourth-quarter earnings that fell short of Wall Street expectations and provided a disappointing forecast for the 2026 financial year.